Drug Trial Radar · NCT06730100
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Sep 11, 2025
Primary completion
Dec 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Dec 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well CBX-12 works in treating patients with microsatellite stable colorectal cancer that has spread to other parts of the body (metastatic) and is no longer responding to chemotherapy treatment (chemotherapy-refractory). The usual approach to treating colorectal cancer includes treatment with surgery, radiation, or Food and Drug Administration (FDA)-approved drugs such as trifluridine-tipiracil, bevacizumab, regorafenib, or fruquintinib. However, most metastatic colorectal patients progress through all approved treatments and eventually succumb to their disease. CBX-12 is a drug that contains a peptide (a substance that contains many amino acids \[molecules that join together to form proteins\]) called pHLIP, linked to an anticancer substance called exatecan. Upon administration, pHLIP gets inserted into the cellular membrane of tumor cells, delivering exatecan to kill them. Giving CBX-12 may work better than the usual approach in treating patients with metastatic chemotherapy-refractory microsatellite stable colorectal cancer.
Conditions
- Metastatic Mismatch Repair Proficient Colorectal Carcinoma
- Refractory Mismatch Repair Proficient Colorectal Carcinoma
- Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT scan
Magnetic Resonance ImagingProcedure
Undergo MRI
pH Low Insertion Peptide-exatecan Conjugate CBX-12Drug
Given IV
X-Ray ImagingProcedure
Undergo chest x-rays
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: From registration to disease progression or death due to any cause, assessed up to 12 months
- Dose limiting toxicities (DLTs)Time frame: Baseline up to 12 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
UF Health Cancer Institute - Gainesville
Gainesville, Florida
Northwestern University
Chicago, Illinois
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland
Montefiore Medical Center-Einstein Campus
The Bronx, New York
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
UT MD Anderson Cancer Center
Houston, Texas
University of Virginia Cancer Center
Charlottesville, Virginia
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.